/

DTIL

Precision BioSciences, Inc.After hours

6.10−0.43 −6.58%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 6.10 0.00%

Open

6.51

Prev close

6.53

Day range

6.056.55

52-week range

3.539.62

Volume

326.68K1.19×

Mkt cap

168.37M

P/E ttm

—

Fwd P/E

-3.28

EPS ttm

-1.35

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−36.59%

Price Chart

Yahoo Finance · delayed

DTILOct 13, 2026O 6.51H 6.55L 6.05C 6.10−0.43 (−6.58%)Vol 326.68K

SMA 507.17
SMA 2006.38

1Y change +8.54% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DTIL Precision BioSciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.61%
1 month: −14.92%
3 months: −28.90%
6 months: −15.63%
Year to date: +46.63%
1 year: +9.71%

Valuation & ownership

Market cap: 168.37M
Enterprise value: 120.79M
P/E (ttm): —
Forward P/E: -3.28
PEG ratio: —
Price / book: 3.56
Price / sales (ttm): 3.74
EV / EBITDA: -3.44
EPS (ttm): -1.35
EPS (forward): -1.86
Beta (5y monthly): 1.27
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 27.60M
Float: 25.45M
Short % of float: 9.33%
Short ratio (days): 9.96
Held by insiders: 8.04%
Held by institutions: 68.71%
Avg volume (3m): 274.71K
50-day average: 7.19
200-day average: 6.37
52-week change: +9.71%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 37.9
vs 50-day SMA: −14.97%
vs 200-day SMA: −4.37%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 6.29%
Realised vol (20d, ann.): 68.1%
From 52-week high: −36.59%
From 52-week low: +72.80%

ANR

Analyst Consensus

5 analysts

Consensus

—

Mean target

29.40

+381.97% implied

Low 18.00Median 20.00High 60.00

Recommendation trend

Now5 / 0 / 0
1m ago5 / 0 / 0

Buy / hold / sell counts

DES

About Precision BioSciences, Inc.

Yahoo Finance profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Sector: Healthcare
Industry: Biotechnology
Employees: 67
Headquarters: Durham, NC, United States
Website: precisionbiosciences.com
Officers: Mr. Michael Amoroso President, CEO & Director
Mr. John Alexander Kelly R.Ph. Chief Operating Officer

SEAS

Seasonality · DTIL

2019–2026 · monthly returns

Strongest month Nov +33.12%Weakest month Mar −22.77%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.8	6.1	31.0	30.0	-2.5	12.8	-11.1	9.3	-18.1	-2.6			+46.6%
2025	31.5	7.6	-11.5	18.2	-14.4	-13.0	13.1	3.2	12.7	47.8	-33.3	-23.5	+9.2%
2024	3.3	63.6	-26.7	-23.2	23.9	-24.6	-2.1	14.2	-17.6	-4.5	-14.8	-47.7	−65.2%
2023	-2.5	-3.4	-32.7	11.4	-11.9	-28.9	9.9	-19.9	-26.3	-9.7	15.3	2.8	−69.3%
2022	-35.5	-10.9	-27.5	-35.4	-15.6	-4.8	-8.1	9.5	-19.3	7.7	-2.1	-13.1	−83.9%
2021	45.3	-1.3	-13.5	-10.2	13.3	18.9	-21.2	27.5	-8.2	-17.8	-4.5	-18.3	−11.3%
2020	-41.8	-1.0	-24.7	14.1	1.9	18.8	-23.6	-11.3	9.2	2.4	97.6	-33.1	−40.0%
2019				-27.6	3.3	-1.3	-2.9	-33.8	-1.5	-22.6	173.8	-21.8	−22.6%

INSD

Insider Activity · DTIL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 27, 2026	Frankel Stanley R.Director	Purchase at price 6.00 per share.	1K	$6.00K
Sep 24, 2026	Germano Geno JDirector	Purchase at price 6.28 per share.	2.6K	$16.39K
Sep 24, 2026	Brown MelindaDirector	Purchase at price 6.27 per share.	1.1K	$7.12K
May 19, 2026	Buehler KevinDirector	—	21K	—
May 19, 2026	Germano Geno JDirector	—	21K	—
May 19, 2026	Brown MelindaDirector	—	21K	—
May 19, 2026	Frankel Stanley R.Director	—	21K	—
May 19, 2026	Pire Shari Lisa J.D.Director	—	21K	—
Feb 17, 2026	Kelly John AlexanderChief Financial Officer	Sale at price 3.84 per share.	8.1K	$31.29K
Feb 17, 2026	Smith J JeffersonOfficer	Sale at price 3.84 per share.	4.9K	$18.91K
Feb 17, 2026	Scimeca Dario JosephGeneral Counsel	Sale at price 3.84 per share.	4.9K	$18.91K
Feb 17, 2026	Amoroso MichaelChief Executive Officer	Sale at price 3.84 per share.	20.6K	$78.95K
Feb 16, 2026	Kelly John AlexanderChief Financial Officer	—	27.6K	—
Feb 16, 2026	Smith J JeffersonOfficer	—	16.7K	—
Feb 16, 2026	Scimeca Dario JosephGeneral Counsel	—	16.7K	—
Feb 16, 2026	Amoroso MichaelChief Executive Officer	—	67.8K	—
Jan 21, 2026	Amoroso MichaelChief Executive Officer	Sale at price 4.17 per share.	34.8K	$145.11K
Jan 20, 2026	Smith J JeffersonOfficer	—	29.2K	—
Jan 20, 2026	Kelly John AlexanderChief Financial Officer	Sale at price 4.03 per share.	15.2K	$61.31K
Jan 20, 2026	Smith J JeffersonOfficer	Sale at price 4.03 per share.	10.2K	$41.11K

13F

Investors Holding DTIL

latest 13F filings of 29 followed managers

Investors holding DTIL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$539.0K	0.00%	68.58K	−69%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

DTIL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DTIL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Precision BioSciences, Inc.

Seasonality · DTIL

Insider Activity · DTIL

Congress Trades · DTIL

Investors Holding DTIL

Investors Holding DTIL

Congress Trades · DTIL

Insider Activity · DTIL

Seasonality · DTIL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Precision BioSciences, Inc.

Financial Snapshot

Earnings & Dividends

News